GlassScriptPhysician profile
Edward Perry Heidtman
NPI 1659472991
$3,327.08
in general payments reported to CMS, 2019-2025
31 companies · $24.27 in 2025
The $24.27 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $730 · 2021: $545 · 2022: $751 · 2023: $659 · 2024: $90.07 · 2025: $24.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $611.25 | 2019-2023 | |
| Hologic Sales and Service, LLC | $463.80 | 2019-2023 | Acessa Provu System, Myosure Tissue Removal Device |
| Medtronic, INC. | $365.78 | 2021-2022 | |
| Gynesonics, INC. | $297.45 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Acessa Health INC. | $188.48 | 2019-2020 | |
| Pfizer INC. | $183.33 | 2019-2023 | |
| Coopersurgical, INC. | $141.15 | 2019-2023 | Summit Doppler |
| Aspira Women'S Health INC | $137.68 | 2021-2023 | Ova1 |
| Therapeuticsmd, INC. | $135.61 | 2019-2022 | |
| Daiichi Sankyo INC. | $115.51 | 2019-2023 | Injectafer |
| Conmed Corporation | $105.07 | 2022 | |
| Roche Diagnostics Corporation | $99.45 | 2019-2021 | |
| Lupin INC. | $75.23 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $46.72 | 2019-2020 | |
| Exact Sciences Corporation | $41.41 | 2023 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $36.36 | 2019 | |
| Astellas Pharma US INC | $32.18 | 2019-2023 | Veozah |
| Mayne Pharma Commercial LLC | $28.95 | 2023 | |
| Amgen INC. | $26.56 | 2021 | |
| Optumhealth Care Solutions, LLC | $24.27 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Duchesnay USA Incorporated | $18.35 | 2019 | |
| Agile Therapeutics, INC. | $17.48 | 2023 | Twirla |
| Davol INC. | $16.25 | 2021 | |
| Avanos Medical | $16.11 | 2022 | |
| Evofem Biosciences, INC. | $16.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.78 | 2022 | |
| Millicent US INC | $15.76 | 2020 | |
| Abbott Laboratories | $14.50 | 2022 | |
| Organon LLC | $14.04 | 2023 | Nexplanon |
| Scynexis, INC. | $13.60 | 2022 | |
| Sumitomo Pharma America, INC. | $12.92 | 2023 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Heidtman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.